Zentalis Pharmaceuticals (NASDAQ: ZNTL) net income
Zentalis Pharmaceuticals reported a net loss of $137.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $165.8m. Earnings per share were −$1.91.
Zentalis Pharmaceuticals's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$137.1m | — | — | −$1.91 |
| 2024 | −$165.8m | — | −246.0% | −$2.33 |
| 2023 | −$292.2m | — | — | −$4.47 |
| 2022 | −$236.8m | — | — | −$4.48 |
| 2021 | −$158.7m | — | — | −$3.72 |
| 2020 | −$117.8m | — | — | −$4.19 |
| 2019 | −$45.7m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Zentalis Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Zentalis Pharmaceuticals ranks 368th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 366th | Kestra Medical Technologies | −$131.6m | −138.4% |
| 367th | NovoCure | −$136.2m | — |
| 368th | Zentalis Pharmaceuticals | −$137.1m | — |
| 369th | Bicara Therapeutics | −$138.0m | — |
| 370th | Inhibrx Biosciences | −$140.1m | −10,773.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Zentalis Pharmaceuticals
- How much did Zentalis Pharmaceuticals earn in fiscal 2025?
- Zentalis Pharmaceuticals reported a net loss of $137.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $165.8m.
- What are the earnings per share of Zentalis Pharmaceuticals?
- They were −$1.91 in fiscal 2025, compared with −$2.33 in fiscal 2024.
- Where does Zentalis Pharmaceuticals rank in its sector by net income?
- It ranks 368th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Zentalis Pharmaceuticals come from?
- From the annual report (Form 10-K) that Zentalis Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Zentalis Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Zentalis Pharmaceuticals: the Zentalis Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.